Drug Sponsors

Abbott, St. Jude Medical broaden alliance for cardiovascular products

Monday, April 23, 2012 02:16 PM

Global pharmaceutical company Abbott and St Jude Medical of St. Paul, Minn., have collaborated on the Choice Alliance, a multi-year joint initiative that provides mutual U.S. customers access to a robust portfolio of interventional cardiology, electrophysiology and intravascular imaging, cardiac rhythm management and diagnostic technologies.

More... »

AZ to acquire Ardea for $1 billion

Monday, April 23, 2012 10:42 AM

Global biopharmaceutical company AstraZeneca has agreed to acquire Ardea Bioscience, a San Diego-based biotechnology company focused on the development of small-molecule therapeutics.

More... »

Biota and Nabi merge to form Biota Pharmaceuticals

Monday, April 23, 2012 09:36 AM

Biota Holdings, an Australian anti-infective drug development company, and Nabi Biopharmaceuticals of Rockville, Md., have signed a Merger Implementation Agreement to form the combined company Biota Pharmaceuticals, to be headquartered in the U.S.

More... »

BioTime and LifeMap to acquire XenneX

Friday, April 20, 2012 02:55 PM

BioTime, a biotech based in Alameda, Calif., and its wholly owned subsidiary LifeMap Sciences have signed a definitive agreement to acquire XenneX through a merger of XenneX into LifeMap Sciences. The acquisition is expected to close within thirty days.

More... »

Cell Therapeutics acquires pacritinib from S*BIO

Friday, April 20, 2012 12:57 PM

Seattle-based Cell Therapeutics (CTI) has purchased worldwide rights to pacritinib from S*BIO, Singapore’s first fully integrated drug discovery company.

More... »

Report: Pharmaceutical market grew by 5.3% in 2011

Friday, April 20, 2012 12:29 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, found that in 2011, the global pharmaceutical market, in dollar terms, benefitted significantly from positive currency effects.

More... »

HGS refuses GSK unsolicited offer, considers alternatives

Friday, April 20, 2012 11:21 AM

Human Genome Sciences has refused GlaxoSmithKline’s unsolicited offer on April 11 proposing to acquire all of the outstanding shares of HGS for $13.00 per share in cash ($2.6 billion), an 81% premium to closing share price on April 18.

More... »

Valeant acquires Atlantis Pharma assets

Wednesday, April 18, 2012 02:59 PM

Valeant Pharmaceuticals International has signed an agreement to acquire certain assets from Atlantis Pharma, a branded generics pharmaceutical company in Mexico, for approximately $71 million.

More... »

Mylan expands in Ireland, creates 500 jobs

Wednesday, April 18, 2012 02:54 PM

Mylan, a generics and specialty pharmaceutical company based in Canonsburg, Penn., will expand its operations in Dublin and Galway, Ireland, by investing up to $100 million over the next five years.

More... »

Five Prime and GSK form second strategic alliance

Wednesday, April 18, 2012 02:28 PM

Five Prime Therapeutics, a biotech based in San Francisco, has entered into its second strategic drug discovery alliance with GlaxoSmithKline in two years.

More... »